Related to IOM Guidelines for Use of Omics Tests in Clinical Trials Add Rigor to Quality Assurance

• Ezose, Hirosaki University Sign Glycomics Partnership to Identify Urologic Cancer Biomarkers
  
• Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D
  
• EU Funds Denator, University Collaboration to Develop Cancer Biomarker Platform
  
• OncoMed Taps Genomic Health to Identify Predictive Biomarkers for Anticancer Antibodies
  
• KineMed, CHDI Ally on Biomarkers of Huntington Disease Progression, Drug Efficacy
  
• Google Search Engine Forms Basis of Algorithm to Identify Prognostic Cancer Biomarkers
  
• XDx, LabCorp to Develop Lupus Flare Predictor Test
  
• Firefly Bags $500K from Massachusetts Life Science Center for miRNA Biomarker Platform
  
• Erytech, ExonHit Share €8.9M Initial OSEO Funding for Enzyme Depletion Anticancer Project
  
• Affymetrix, MGH Team Up to Develop Biomarker Tests Using QuantiGene ViewRNA Platform
  
• Biomarker Diagnostics Firm Astute Raises $40.4M in Series C Fundraising
  
• Population Genetics, Oxford University Partner on Biomarkers for in MI, Diabetes, Metabolic Disease
  
• BGI, Children's Hospital of Philadelphia Start 1,000 Rare Diseases Project
  
• Companion Dx Negotiates License to Epigenomics’ Septin9 Blood Biomarker for CRC Test
  
• Gentris, China’s SIPM Collaborate on Biomarker Discovery
  
• Merck Serono, Compugen Establish Biomarkers Firm Neviah Genomics
  
• VTT Joins with GE Healthcare to Validate Alzheimer Disease Biomarker
  
• KineMed Wins $1.2M from MJFF for Parkinson Disease Biomarker Program
  
• Plexpress, Phalanx Offer Biomarker Discovery and Validation Service
  
• Janssen Commits $5.4M to Multiple Sclerosis Initiative